Technical Analysis for RXDX - Prometheus Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical RXDX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.50% | |
| Narrow Range Bar | Range Contraction | -2.50% | |
| NR7 | Range Contraction | -2.50% | |
| Stochastic Reached Oversold | Weakness | -2.50% | |
| Wide Bands | Range Expansion | -2.50% | |
| Oversold Stochastic | Weakness | -2.50% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.32% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 11 hours ago |
| Down 3% | about 13 hours ago |
| Down 2 % | about 13 hours ago |
| Non-ADX 1,2,3,4 Bearish Retracement Entry | about 13 hours ago |
| Fell Below Previous Day's Low | about 13 hours ago |
Get a Trading Assistant
- Earnings date: ???
Prometheus Biosciences, Inc. Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Immunology Inflammatory Bowel Disease Tumor Necrosis Factor Inflammatory Bowel Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 30.64 |
| 52 Week Low | 16.11 |
| Average Volume | 200,653 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 22.81 |
| 20-Day Moving Average | 23.69 |
| 10-Day Moving Average | 21.56 |
| Average True Range | 1.91 |
| ADX | 14.3 |
| +DI | 19.67 |
| -DI | 19.26 |
| Chandelier Exit (Long, 3 ATRs) | 21.99 |
| Chandelier Exit (Short, 3 ATRs) | 26.20 |
| Upper Bollinger Bands | 28.30 |
| Lower Bollinger Band | 19.07 |
| Percent B (%b) | 0.21 |
| BandWidth | 38.96 |
| MACD Line | -0.59 |
| MACD Signal Line | -0.23 |
| MACD Histogram | -0.3638 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 22.34 | ||||
| Resistance 3 (R3) | 22.40 | 22.03 | 22.13 | ||
| Resistance 2 (R2) | 22.03 | 21.70 | 22.00 | 22.05 | |
| Resistance 1 (R1) | 21.54 | 21.50 | 21.36 | 21.48 | 21.98 |
| Pivot Point | 21.17 | 21.17 | 21.08 | 21.14 | 21.17 |
| Support 1 (S1) | 20.68 | 20.84 | 20.50 | 20.62 | 20.12 |
| Support 2 (S2) | 20.31 | 20.64 | 20.28 | 20.05 | |
| Support 3 (S3) | 19.82 | 20.31 | 19.98 | ||
| Support 4 (S4) | 19.76 |
